The effects of acarbose combined with metformin on inflammatory factors and cellular immune function in patients with type 2 diabetes mellitus
-
摘要: 目的 探讨阿卡波糖联合二甲双胍对2型糖尿病患者的临床疗效及作用机制。 方法 将114例2型糖尿病患者随机分为联合治疗组(n=58)、二甲双胍组(n=56)。二甲双胍组给予二甲双胍治疗,联合治疗组给予阿卡波糖联合二甲双胍治疗。治疗3个月后,比较2组血清炎性因子、T淋巴细胞亚群、血糖控制、不良反应发生率。 结果 联合治疗组血清白细胞介素-6(IL-6)、C-反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)水平低于二甲双胍组(P<0.05), CD3+、CD4+、CD4+/CD8+高于二甲双胍组, CD8+低于二甲双胍组,差异有统计学意义(P<0.05)。联合治疗组空腹血糖(FPG)、空腹胰岛素(FINS)、糖化血红蛋白(HbA1c)、胰岛素抵抗指数(HOMA-IR)低于二甲双胍组,差异有统计学意义(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。 结论 阿卡波糖联合二甲双胍可抑制2型糖尿病患者的炎症反应,并调节其细胞免疫功功能和血糖水平。Abstract: Objective To explore the clinical effect of acarbose combined with metformin for patients with type 2 diabetes mellitus and its mechanism of action. Methods A total of 114 patients with type 2 diabetes were randomly divided into combined treatment group(n=58)and metformin group(n=56). The metformin group was treated with metformin, while the combined treatment group was given acarbose combined with metformin. After 3 months of treatment, serum inflammatory factors, T lymphocyte subsets, blood glucose control and incidence of adverse reactions were compared between the two groups. Results The levels of serum interleukin-6(IL-6), C-reactive protein(CRP)and tumor necrosis factor-α(TNF-α)in the combined treatment group were significantly lower than those in the metformin group(P<0.05), CD3+, CD4+, CD4+/CD8+ in the combined treatment group were significantly higher than those in the metformin group, and CD8+ was significantly lower than that in the metformin group(P<0.05). Fasting blood gluscose(FPG), fasting insulin(FINS), Hemoglobin A1c(HbA1c)and homeostasis model assessment of insulin resistance(HOMA-IR)in the combined treatment group were significantly lower than those in the metformin group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion Acarbose combined with metformin can inhibit the inflammatory response of patients with type 2 diabetes mellitus, and regulate their cellular immune function and blood glucose level.
-
Keywords:
- type 2 diabetes mellitus /
- acarbose /
- metformin /
- inflammatory factors /
- T lymphocytes
-
-
PAN Q, XU Y, YANG N, et al. Metformin or acarbose treatment significantly reduced albuminuria in patients with newly diagnosed type 2 diabetes mellitus and low-grade albuminuria[J]. Med Sci Monit, 2018, 24: 8941-8949.
OU H T, CHEN Y T, LIU Y M, et al. Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan[J]. Diabetes Res Clin Pract, 2016, 116: 14-25.
MOELANDS S V, LUCASSEN P L, AKKERMANS R P, et al. Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus[J]. Cochrane Database Syst Rev, 2018, 12(12): CD005061.
AKASH M S H, REHMAN K, LIAQAT A. Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus[J]. J Cell Biochem, 2018, 119(1): 105-110.
ABOUZEID S, SHERIF N. Role of alteration in Treg/Th17 cells' balance in nephropathic patients with Type 2 diabetes mellitus[J]. Electron Physician, 2015, 7(8): 1613-1618.
WANG L M, GAO P, ZHANG M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013[J]. JAMA, 2017, 317(24): 2515-2523.
ZHANG Q G, WANG C Q, XUE S, et al. Comparison of acarbose and metformin as add-on therapy to isulin in uncontrolled patients with type 2 diabetes mellitus: A randomized, open-labeled, and parallel group study[J]. Chin J Endocrinol Metab, 2018, 34(9): 755-760.
VOS R C, VAN AVENDONK M J, JANSEN H, et al. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control[J]. Cochrane Database Syst Rev, 2016, 9(9): CD006992.
张丽菊, 李为民. 阿卡波糖联合二甲双胍治疗2型糖尿病伴高血脂症疗效的回顾性研究[J]. 中国药师, 2017, 20(2): 284-286. ZHANG J, JIN J, LIU J L, et al. A study of the correlation of insulin resistance and leptin with inflammatory factors and vascular endothelial injury in T2DM patients with CHD[J]. Exp Ther Med, 2018, 16(1): 265-269.
HOFMEISTER M. Comment on: efficacy of Omega-3 fatty acid supplementation on serum levels of tumour necrosis factor-alpha, C-reactive protein and interleukin-2 in type 2 diabetes mellitus patients[J]. Singapore Med J, 2013, 54(1): 53-53.
PHOSAT C, PANPRATHIP P, CHUMPATHAT N, et al. Elevated C-reactive protein, interleukin 6, tumor necrosis factor alpha and glycemic load associated with type 2 diabetes mellitus in rural Thais: a cross-sectional study[J]. BMC Endocr Disord, 2017, 17(1): 44-52.
蔡凤, 刘钜荣, 范德美, 等. 二甲双胍对2型糖尿病大鼠非酒精性脂肪性肝病相关慢性炎症反应的影响[J]. 实用医学杂志, 2018, 34(12): 1965-1969. SU B L, LIU H X, LI J, et al. Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus[J]. J Diabetes, 2015, 7(5): 729-739.
曹永, 王宏宇, 徐春. 天芪降糖胶囊联合二甲双胍对2型糖尿病患者白介素6、肿瘤坏死因子α和C反应蛋白的影响[J]. 中国糖尿病杂志, 2015, 23(8): 739-741. KIM S A, Choi H C. Metformin inhibits inflammatory response via AMPK-PTEN pathway in vascular smooth muscle cell[J]. Biochem Biophys Res Commun, 2012, 425(4): 866-872.
PANG N, CHEN K, PENG H J, et al. Effect of Acarbose Combined with Metformin on Related Indexes of Patients with Type 2 Diabetes[J]. China Pharmacy, 2017, 28(27): 3774-3777.
SHEIKH V, ZAMANI A, MAHABADI-ASHTIYANI E, et al. Decreased regulatory function of CD4+CD25+CD45RA+ T cells and impaired IL-2 signalling pathway in patients with type 2 diabetes mellitus[J]. Scand J Immunol, 2018, 88(4): e12711.
DU J, LIANG L, FANG H, et al. Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase Ⅳ open-label randomized controlled study(the SMART study)[J]. Diabetes Obes Metab, 2017, 19(11): 1513-1520.
MAHMOUD F F, HAINES D, DASHTI A A, et al. Correlation between heat shock proteins, adiponectin, and T lymphocyte cytokine expression in type 2 diabetics[J]. Cell Stress Chaperones, 2018, 23(5): 955-965.
KIM E K, LEE S H, JHUN J Y, et al. Metformin prevents fatty liver and improves balance of white/brown adipose in an obesity mouse model by inducing FGF21[J]. Mediators Inflamm, 2016, 2016: 5813030.
LEE S Y, LEE S H, YANG E J, et al. Metformin ameliorates inflammatory bowel disease by suppression of the STAT3 signaling pathway and regulation of the between Th17/treg balance[J]. PLoS One, 2015, 10(9): e0135858.
GAO L Y, LIU J Q, YANG S J, et al. Effect on T cell subsets and function of isletβ cells of levemir combined with acarbose in elder patients with early-onset type 2 Diabetes Mellitus[J]. 海南医科大学学报: 英文版, 2017, 23(2): 74-77. -
期刊类型引用(31)
1. 黄奇峰，郑鹏程，戴燕玲. 二甲双胍、阿卡波糖分别联用厄贝沙坦治疗糖尿病合并高血压的临床效果比较. 糖尿病新世界. 2024(04): 56-59+66 . 
百度学术
2. 孙燕，张新菊，李雁. 卡格列净在基层糖尿病慢病管理中的疗效观察. 兵团医学. 2024(01): 54-56 . 百度学术
3. 黄延峰，钟荣惠. 甘精胰岛素搭配阿卡波糖和二甲双胍对糖尿病控制和氧化应激的影响研究. 现代医学与健康研究电子杂志. 2024(12): 51-54 . 百度学术
4. 程继华，孟俊娜，雷巧玲. 艾塞那肽治疗2型糖尿病的疗效及对胰岛素抵抗与糖脂代谢的影响研究. 中国医学工程. 2024(08): 88-92 . 百度学术
5. 贾志壮. 阿卡波糖联合二甲双胍治疗2型糖尿病的效果. 名医. 2024(09): 165-167 . 百度学术
6. 黄伟玲. 阿卡波糖联合二甲双胍治疗2型糖尿病对免疫功能及不良反应的影响. 临床合理用药. 2024(28): 103-105+115 . 百度学术
7. 任喆. 阿卡波糖联合二甲双胍在社区糖尿病患者糖代谢控制中的应用效果. 中国社区医师. 2024(32): 26-28 . 百度学术
8. 张秀丽，余玉花，张文帝. 二甲双胍联合阿卡波糖对2型糖尿病患者免疫功能、糖脂代谢的影响. 糖尿病新世界. 2024(18): 86-88+92 . 百度学术
9. 林钧，陈玮，刘进清. 视网膜激光光凝术与阿卡波糖联合治疗糖尿病性黄斑水肿的临床疗效. 糖尿病新世界. 2024(23): 187-190 . 百度学术
10. 岳斌，张巍，徐丽，郑华东，李明. 二甲双胍联合阿卡波糖治疗2型糖尿病的疗效及对免疫功能和NLRP3水平的影响. 海南医学. 2023(01): 14-18 . 百度学术
11. 耿瑶. 探究达格列净治疗2型糖尿病并心衰的临床疗效及其对炎性因子、血管内皮功能的影响. 黑龙江医学. 2023(05): 547-550 . 百度学术
12. 王鑫. 阿卡波糖联合二甲双胍治疗2型糖尿病的临床疗效观察. 现代诊断与治疗. 2023(01): 64-66+69 . 百度学术
13. 卢洁菲. 阿卡波糖联合二甲双胍对2型糖尿病患者免疫功能及炎性因子的影响. 甘肃医药. 2023(04): 318-319+325 . 百度学术
14. 景珊. 二甲双胍联合阿卡波糖用于糖尿病治疗的疗效及对HbA1c、FPG水平的影响分析. 糖尿病新世界. 2023(09): 76-79 . 百度学术
15. 孙嘉婧，于湘英，马子良. 阿卡波糖与二甲双胍在社区糖尿病治疗中的效果及对血糖的影响探析. 糖尿病新世界. 2023(10): 108-111+115 . 百度学术
16. 卢凯丽，宋瑞捧，姜惠惠，高红红. 阿卡波糖联合维格列汀治疗初治2型糖尿病的效果及对糖脂代谢的影响. 中国实用医刊. 2023(14): 109-112 . 百度学术
17. 方信英. 二甲双胍联合阿卡波糖在2型糖尿病患者中的应用效果分析. 糖尿病新世界. 2023(23): 81-84 . 百度学术
18. 仲伟慧. 阿卡波糖联合二甲双胍治疗2型糖尿病的疗效分析. 中国社区医师. 2022(06): 76-77+80 . 百度学术
19. 刘燕君，朱明敏，陈亚东. 二甲双胍与预混胰岛素联用对2型糖尿病患者血糖指标水平与不良反应的影响. 糖尿病新世界. 2022(05): 68-71 . 百度学术
20. 刘婷，王莹，杨召娣，陈继芳. 阿卡波糖联合二甲双胍治疗2型糖尿病对患者血糖水平、胰岛功能的影响. 现代医学与健康研究电子杂志. 2022(12): 142-144 . 百度学术
21. 王云枫，王彦贺. 阿卡波糖对2型糖尿病患者血脂及尿酸代谢的影响. 哈尔滨医药. 2022(03): 62-63 . 百度学术
22. 王学光. 二甲双胍联合阿卡波糖治疗2型糖尿病临床疗效分析. 糖尿病新世界. 2022(11): 102-105 . 百度学术
23. 陈聪，梁黎黎. 有氧-抗阻运动指导联合降糖药物对老年糖尿病患者的应用效果. 现代医学与健康研究电子杂志. 2022(21): 141-144 . 百度学术
24. 张建，范文文. DPP-4抑制剂联合阿卡波糖治疗初诊老年T2DM患者的疗效分析. 国际医药卫生导报. 2022(23): 3388-3391 . 百度学术
25. 黄文新. 瑞格列奈结合二甲双胍治疗2型糖尿病的疗效及对患者血糖水平的影响. 糖尿病新世界. 2021(07): 87-89 . 百度学术
26. 阳玲，黄冠军，方涛，柴振华，朱红艳. 二甲双胍联合阿格列汀或阿卡波糖治疗2型糖尿病的疗效对比. 药品评价. 2021(10): 621-623 . 百度学术
27. 徐露，章晓君. 阿卡波糖联合二甲双胍治疗糖尿病前期患者的效果分析. 现代医学与健康研究电子杂志. 2021(15): 51-53 . 百度学术
28. 房思思，屈桂茹. 拜糖平和二甲双胍治疗2型糖尿病的有效性及安全性研究. 中国药物滥用防治杂志. 2021(05): 682-684+703 . 百度学术
29. 周芸，刘路. 阿卡波糖联合二甲双胍对2型糖尿病患者血糖与肠促胰岛素水平的影响. 现代医学与健康研究电子杂志. 2021(18): 45-47 . 百度学术
30. 李黎，张瑞. 阿卡波糖联合二甲双胍用于治疗2型糖尿病临床效果分析. 世界复合医学. 2021(10): 195-198 . 百度学术
31. 宋先梅. 二甲双胍结合阿卡波糖治疗初发2型糖尿病伴高脂血症的临床效果分析. 中国现代药物应用. 2021(23): 139-141 . 百度学术
其他类型引用(0)
计量
- 文章访问数: 303
- HTML全文浏览量: 98
- PDF下载量: 17
- 被引次数: 31
下载:
苏公网安备 32100302010246号